All In Biotech

Drug Trial Radar · NCT00400153

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Jun 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,480

Actual

Start

Nov 2006

Primary completion

Apr 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Atrovent Respimat (20 mcg)Drug

  • COMBIVENT MDI (36/206 mcg)Drug

  • Combivent Respimat (20 mcg/100 mcg)Drug

  • Placebo via corresponding inhaler for blinding purposesDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 AUC0-6 at Day 85Time frame: Before drug administration to 6 hours after drug administration on Day 85
  2. FEV1 AUC0-4 at Day 85Time frame: Before drug administration to 4 hours after drug administration on Day 85
  3. FEV1 AUC4-6 at Day 85Time frame: Between 4 hours and 6 hours after drug administration on Day 85

Locations

180 sites in 13 countries. Site status is shown where the registry gives one.

  • 1012.56.01006 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1012.56.01051 Boehringer Ingelheim Investigational Site

    Jasper, Alabama

  • 1012.56.01071 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1012.56.01039 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1012.56.01012 Boehringer Ingelheim Investigational Site

    Lakewood, California

  • 1012.56.01029 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1012.56.01043 Boehringer Ingelheim Investigational Site

    Palo Alto, California

  • 1012.56.01089 Boehringer Ingelheim Investigational Site

    Rancho Mirage, California

  • 1012.56.01021 Boehringer Ingelheim Investigational Site

    Riverside, California

  • 1012.56.01033 Boehringer Ingelheim Investigational Site

    San Jose, California

  • 1012.56.01020 Boehringer Ingelheim Investigational Site

    Sepulveda, California

  • 1012.56.01045 Boehringer Ingelheim Investigational Site

    Torrence, California

  • 1012.56.01040 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1012.56.01050 Boehringer Ingelheim Investigational Site

    Fort Collins, Colorado

  • 1012.56.01018 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1012.56.01062 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 1012.56.01036 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 1012.56.01025 Boehringer Ingelheim Investigational Site

    Stamford, Connecticut

  • 1012.56.01088 Boehringer Ingelheim Investigational Site

    Waterbury, Connecticut

  • 1012.56.01007 Boehringer Ingelheim Investigational Site

    Bay Pines, Florida

  • 1012.56.01058 Boehringer Ingelheim Investigational Site

    Brandon, Florida

  • 1012.56.01010 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1012.56.01065 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1012.56.01024 Boehringer Ingelheim Investigational Site

    DeLand, Florida

  • 1012.56.01001 Boehringer Ingelheim Investigational Site

    Melbourne, Florida

  • 1012.56.01023 Boehringer Ingelheim Investigational Site

    Panama City, Florida

  • 1012.56.01052 Boehringer Ingelheim Investigational Site

    Pensecola, Florida

  • 1012.56.01048 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1012.56.01093 Boehringer Ingelheim Investigational Site

    Winter Park, Florida

  • 1012.56.01077 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1012.56.01083 Boehringer Ingelheim Investigational Site

    Decatur, Georgia

  • 1012.56.01008 Boehringer Ingelheim Investigational Site

    Coeur d'Alene, Idaho

  • 1012.56.01019 Boehringer Ingelheim Investigational Site

    Olathe, Kansas

  • 1012.56.01056 Boehringer Ingelheim Investigational Site

    Wichita, Kansas

  • 1012.56.01066 Boehringer Ingelheim Investigational Site

    Bowling Green, Kentucky

  • 1012.56.01090 Boehringer Ingelheim Investigational Site

    Lafayette, Louisiana

  • 1012.56.01054 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 1012.56.01072 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 1012.56.01070 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

  • 1012.56.01035 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.